DNA Synthesis Market Size, Share, Trends, Industry Analysis Report
By Type (Oligonucleotide Synthesis and Gene Synthesis), By Application, By End-User, and By Region – Market Forecast, 2025–2034
- Published Date:Aug-2025
- Pages: 125
- Format: PDF
- Report ID: PM2944
- Base Year: 2024
- Historical Data: 2020-2023
Overview
The global DNA synthesis market size was valued at USD 3.66 billion in 2024, growing at a CAGR of 18.65% from 2025 to 2034. Key factors driving demand for DNA synthesis include strong growth in the biopharmaceutical industry coupled with increasing integration of automation and AI in DNA synthesis workflows.
Key Insights
- The oligonucleotide synthesis materials segment dominated the market share in 2024.
- The therapeutics segment is projected to grow at a rapid pace in the coming years, fueled by rising demand for gene therapies, personalized medicine, biologics, and precision therapeutics that require precise and scalable DNA constructs.
- The North America DNA Synthesis market dominated the global market share in 2024.
- The U.S. DNA synthesis market is growing, due to the rising public funding programs for promoting genomics and molecular biology initiatives across the country.
- The market in Asia Pacific is projected to grow at a fast pace from 2025-2034, fueled by rising investments in genomics, molecular diagnostics, and vaccine development.
- The market in India is growing, propelled by the rapid growth of the pharmaceutical industry and expanding R&D infrastructure.
Industry Dynamics
- Strong growth in the biopharmaceutical industry is driving adoption of DNA synthesis technologies, as companies leverage synthetic DNA for drug discovery, biologics production, and vaccine development.
- Increasing integration of automation and AI in DNA synthesis workflows is enhancing efficiency, accuracy, and scalability, boosting wider utilization across research and industrial applications.
- Development of enzymatic DNA synthesis platforms presents significant growth opportunities, offering faster, more precise, and scalable production of long DNA sequences.
- High research and development (R&D) costs associated with advanced DNA synthesis technologies continue to restrain market growth, limiting accessibility for smaller organizations and slowing broader adoption.
Market Statistics
- 2024 Market Size: USD 3.66 Billion
- 2034 Projected Market Size: USD 17.36 Billion
- CAGR (2025–2034): 18.65%
- North America: Largest Market Share
AI Impact on DNA Synthesis Market
- AI enhances performance optimization in the DNA synthesis market by analyzing synthesis protocols, sequence complexity, and reagent interactions to ensure high-yield and error-free oligonucleotide production.
- Integration of AI enables adaptive synthesis control, dynamically adjusting reaction parameters such as temperature, timing, and reagent flow based on real-time monitoring of DNA strand formation and error detection.
- AI-powered analytics assist in early identification of synthesis failures, reagent degradation, or contamination risks, supporting predictive maintenance and reducing waste in biotech manufacturing facilities.
- AI improves researcher interaction by enabling automated sequence design, real-time troubleshooting, and optimized workflow recommendations, accelerating R&D timelines and increasing throughput in genomic research and synthetic biology applications.
The DNA synthesis market encompasses advanced methods and platforms designed to construct DNA sequences with accuracy, flexibility, and efficiency. Extensively applied across pharmaceuticals, biotechnology, diagnostics, agriculture, and academic research, DNA synthesis facilitates gene editing, synthetic biology applications, and the creation of novel biomolecules. Rising improvements in chemical and enzymatic synthesis technologies, automation systems, and quality-control processes are enhancing speed, reliability, and scalability. Providing tailored solutions for large-scale research, personalized medicine, and industrial biotechnology, DNA synthesis supports innovation in genomics, strengthens drug discovery services, and enables progress in healthcare, agriculture, and bioengineering.
The rising prevalence of genetic disorders is boosting the investment in novel DNA synthesis platforms for gene therapy research, diagnostics, and personalized treatment development. The World Health Organization estimates that 10 out of every 1,000 people are affected by genetic diseases, which translated to between 70 million and 80 million individuals worldwide. This growing disease burden is increasing the demand for advanced DNA synthesis technologies capable of producing high-fidelity sequences tailored for therapeutic applications. Expanding adoption in oncology, rare disease research, and regenerative medicine is further propelling market growth.
Expanding applications in synthetic biology are accelerating advancements in gene circuits, engineered microbes, and metabolic pathway engineering, enabling innovative solutions for industrial biotechnology, therapeutic development, and sustainable production systems. Continuous improvements in DNA synthesis platforms, automation, and error-correction methods are enhancing the ability to generate long, accurate DNA sequences, accelerating innovations in biomanufacturing, precision medicine, and renewable energy. The integration of DNA synthesis into synthetic biology research are further strengthening the development of engineered enzymes, biomolecules, and tailored biological systems that address crucial needs across pharmaceuticals, agriculture, and bio-based industries.
Drivers & Opportunities
Strong Growth in the Biopharmaceutical Industry Driving Utilization of DNA Synthesis in Drug Discovery, Biologics, and Vaccine Development: The rapid expansion of the global biopharmaceutical sector is boosting demand for DNA synthesis technologies. DNA synthesis provides the foundation for gene constructs, antibody libraries, and synthetic vaccine candidates that support faster and more efficient R&D cycles. According to India’s Ministry of Science & Technology, the country’s biopharmaceutical industry grew from USD 10 billion in 2014 to USD 165.7 billion in 2024, with projections to surpass USD 300 billion by 2030. This growth reflects rising investment in genomics, biomanufacturing, and advanced therapeutics, propelling the strategic importance of DNA synthesis in accelerating innovation across pharmaceuticals and healthcare.
Increasing Integration of Automation and AI in DNA Synthesis Workflows: Rising integration of automation and artificial intelligence into DNA synthesis workflows to optimize design, improve accuracy, and scale production, is driving the market growth. Advanced AI-driven platforms enable faster error detection, automated sequence validation, and streamlined high-throughput synthesis, reducing costs and timelines for complex DNA constructs. For example, in October 2024, researchers at Yale School of Medicine, the Jackson Laboratory, and the Broad Institute introduced CODA (Computational Optimization of DNA Activity), a generative AI platform designed to engineer synthetic cis-regulatory DNA elements (CREs) with high precision in cell-type-specific gene activation. CODA significantly outperformed natural sequences in specificity and efficacy, highlighting the transformative role of AI and automation in reshaping DNA synthesis for research, therapeutics, and synthetic biology applications.
Segmental Insights
By Type
Based on type, the market is divided into oligonucleotide synthesis and gene synthesis. The oligonucleotide synthesis segment held the largest market share in 2024, due to its widespread application in PCR assays, next-generation sequencing, molecular diagnostics, and targeted therapeutic research. Its crucial role in enabling high-throughput genetic analysis and diagnostic assays for infectious diseases, oncology, and personalized medicine established it as the most utilized type in the DNA synthesis industry.
The gene synthesis segment is expected to register the fastest growth during the forecast period, owing to its increasing adoption in synthetic biology, genetic engineering, vaccine development, and large-scale DNA assembly for advanced therapeutics and biotechnological innovations. The segment is growing due to the rising demand for complex DNA constructs and engineered organisms that enable innovations in metabolic engineering, bio-based materials, and next-generation drug development.
By Application
In terms of application, the market is segmented into diagnostics, therapeutics, and research & development. The diagnostics segment dominated the market in 2024, attributed to the increasing adoption of DNA-based assays, biomarker discovery, and infectious disease detection across healthcare, research, and clinical settings. Applications in early disease detection, personalized diagnostics, and precision medicine is increasing the demand for high-quality synthetic DNA for accurate and rapid testing solutions.
The therapeutics segment is projected to grow at the fastest rate during the forecast period, fueled by rising demand for gene therapies, personalized medicine, biologics, and precision therapeutics that require precise and scalable DNA constructs. Increasing focus on rare diseases, oncology treatments, and advanced molecular therapies is boosting adoption of DNA synthesis technologies capable of supporting large-scale production, high-fidelity sequences, and rapid turnaround times.
By End-User
Based on end-user, the market is classified into pharmaceutical & biotechnology companies, contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs), and others. The pharmaceutical & biotechnology companies segment accounted for the largest share in 2024, due to growing utilization of DNA synthesis in drug discovery, development of gene therapies, biologics, and research-driven innovation. These companies rely extensively on synthetic DNA to design, test, and manufacture advanced therapeutic solutions, driving consistent demand for high-quality products.
The CROs and CDMOs segment is expected to grow the fastest, supported by the global trend of outsourcing DNA synthesis services to reduce operational costs, enhance scalability, and accelerate research timelines. Increasing adoption of third-party providers offering automated workflows, precision synthesis, and customized DNA constructs is enabling smaller firms, startups, and research institutes to access cutting-edge solutions, driving substantial market growth.
Regional Analysis
The North America DNA synthesis market accounted for the largest share in 2024, attributed to the strong presence of leading biotechnology and pharmaceutical companies that are driving demand for custom DNA constructs. Expanding applications in gene therapy, synthetic biology, and CRISPR-based research are further strengthening adoption of advanced DNA synthesis solutions across the region. Substantial government funding and private investment in genomics and molecular biology research are enhancing market growth, coupled with collaborations between academic institutions and biopharma firms, accelerating innovation and commercialization of synthetic DNA technologies.
U.S. DNA Synthesis Market Analysis
The U.S. DNA synthesis market held a dominant position in North America, due to the rising public funding programs for promoting genomics and molecular biology initiatives across the country. For instance, in September 2024, the National Institutes of Health (NIH) awarded USD 5.4 million in first-year funding to establish a program integrating genomics into learning health systems across the U.S. These initiatives highlight strong federal support for genomic innovation that boosts the demand for DNA synthesis in research and therapeutic development.
Asia Pacific DNA Synthesis Market Insights
The Asia Pacific DNA synthesis market is projected to witness the fastest growth over the forecast period, fueled by rising investments in genomics, molecular diagnostics, and vaccine development. Expansion of academic and research institutions across the region is driving the adoption of advanced DNA synthesis technologies for therapeutic and industrial applications. Increasing biotechnology-driven innovation in countries such as India, China, Japan, and South Korea is further accelerating the growth of the market.
India DNA Synthesis Market Analysis
India held significant share within the Asia Pacific market, propelled by the rapid growth of the pharmaceutical industry and expanding R&D infrastructure. According to the International Society for Pharmaceutical Engineering (ISPE), as of 2023, India ranked as the third-largest producer of drugs and pharmaceuticals by volume, accounting for a 20% global share in generic drug exports. Valued at approximately USD 50 billion, the industry aims to reach USD 450 billion by 2047. This significant growth is boosting the demand for advanced DNA synthesis technologies to support drug discovery, vaccine production, and genomics research.
Europe DNA Synthesis Market Assessment
The Europe DNA synthesis market accounted for a substantial share globally in 2024, driven by strong government support and funding for genomic research, biobanking, and synthetic biology initiatives. High adoption of CRISPR and synthetic biology technologies in academic and industrial R&D is further fueling the demand for precise and scalable DNA synthesis solutions. EU-funded projects, such as Horizon Europe, are facilitating large-scale genomics, agricultural biotechnology, and bioeconomy programs, enabling widespread deployment of DNA synthesis technologies across healthcare, research, and industrial biotechnology applications.
Key Players & Competitive Analysis
The global DNA synthesis market is highly competitive, with leading players such as Twist Bioscience Corporation, DNA Script SAS, and Molecular Assemblies, Inc. driving the industry through innovations in high-throughput synthesis platforms, custom DNA constructs, and scalable production technologies. Twist Bioscience Corporation continues to expand its portfolio of synthetic DNA products for genomics, therapeutics, and industrial biotechnology applications, while DNA Script SAS strengthens its market position with benchtop DNA synthesis systems enabling on-demand oligonucleotide production. Molecular Assemblies, Inc. focuses on developing next-generation DNA synthesis methods that provide higher accuracy, faster turnaround, and reduced reliance on traditional chemical reagents.
The market is experiencing rising adoption of DNA synthesis across pharmaceutical, biotechnology, and academic research applications, fueled by demand for precision, scalability, and automation in gene assembly and sequence design. Companies are increasingly offering integrated platforms that combine automation, AI-driven sequence optimization, and high-throughput workflows to improve efficiency and reduce costs. Strategic collaborations with pharmaceutical firms, contract research organizations (CROs), and academic institutions are accelerating commercialization, while sustainability-focused initiatives aimed at minimizing chemical waste are enhancing the attractiveness of modern DNA synthesis solutions as environmentally responsible alternatives to conventional phosphoramidite chemistry.
Prominent companies operating in the DNA synthesis market include BIONEER CORPORATION, Camena Bioscience Ltd., DNA Script SAS, Eton Bioscience, Inc., Eurofins Scientific SE, GenScript Biotech Corporation, IBA Lifesciences GmbH, Integrated DNA Technologies, Inc., LGC Biosearch Technologies Limited, Molecular Assemblies, Inc., Quintara Biosciences, Inc., Synbio Technologies, Inc., Thermo Fisher Scientific, Inc., Touchlight Genetics Ltd., and Twist Bioscience Corporation.
Key Players
- BIONEER CORPORATION
- Camena Bioscience Ltd.
- DNA Script SAS
- Eton Bioscience, Inc.
- Eurofins Scientific SE
- GenScript Biotech Corporation
- IBA Lifesciences GmbH
- Integrated DNA Technologies, Inc.
- LGC Biosearch Technologies Limited
- Molecular Assemblies, Inc.
- Quintara Biosciences, Inc.
- Synbio Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Touchlight Genetics Ltd.
- Twist Bioscience Corporation
DNA Synthesis Industry Developments
In May 2025, Twist Bioscience and Ginkgo Bioworks updated collaboration, moving to a three-year agreement. Ginkgo continues annual prepayments for Twist’s synthetic DNA products without a minimum purchase, while Twist gains licenses for certain long DNA technologies, boosting its synthetic biology portfolio.
In March 2025, Integrated DNA Technologies (IDT) partnered with Elegen to enhance long DNA synthesis capabilities. IDT customers gained early access to Elegen’s ENFINIA Plasmid DNA service, enabling rapid delivery of complex genes from 5 kb to 15 kb, strengthening IDT’s offerings for cell and gene therapy, metabolic engineering, and synthetic genome research.
DNA Synthesis Market Segmentation
By Type Outlook (Revenue, USD Billion, 2020–2034)
- Oligonucleotide Synthesis
- Gene Synthesis
By Application Outlook (Revenue, USD Billion, 2020–2034)
- Diagnostics
- Infectious Diseases
- Cancer
- Others
- Therapeutics
- Gene Therapy
- Preventive Medicine
- Others
- Research & Development
- Cloning and Gene Editing
- Drug Discovery & Development
- Others
By End-User Outlook (Revenue, USD Billion, 2020–2034)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
- Others
By Regional Outlook (Revenue, USD Billion, 2020–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
DNA Synthesis Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 1.82 Billion |
|
Market Size in 2025 |
USD 1.91 Billion |
|
Revenue Forecast by 2034 |
USD 3.01 Billion |
|
CAGR |
18.65% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 1.82 billion in 2024 and is projected to grow to USD 3.01 billion by 2034.
The global market is projected to register a CAGR of 18.65%% during the forecast period.
North America dominated the market in 2024.
A few of the key players in the market are BIONEER CORPORATION, Camena Bioscience Ltd., DNA Script SAS, Eton Bioscience, Inc., Eurofins Scientific SE, GenScript Biotech Corporation, IBA Lifesciences GmbH, Integrated DNA Technologies, Inc., LGC Biosearch Technologies Limited, Molecular Assemblies, Inc., Quintara Biosciences, Inc., Synbio Technologies, Inc., Thermo Fisher Scientific, Inc., Touchlight Genetics Ltd., and Twist Bioscience Corporation.
The oligonucleotide synthesis segment dominated the market revenue share in 2024, due to its widespread application in PCR assays, next-generation sequencing, molecular diagnostics, and targeted therapeutic research.
The therapeutics segment is projected to witness the fastest growth during the forecast period, fueled by rising demand for gene therapies, personalized medicine, biologics, and precision therapeutics that require precise and scalable DNA constructs.
© 2025 Polaris Market Research and Consulting. All rights reserved
